Ginkgo Bioworks Holdings Inc vs Fabrinet — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.46 (market cap $505.73M), while Fabrinet trades at $583.49 (market cap $18.84B). The key difference: Fabrinet is far larger — about 37.3× Ginkgo Bioworks Holdings Inc's market cap, and Fabrinet is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | FN | |
|---|---|---|
Market Cap | $505.73M | $18.84B |
Sector | Health | Technology |
52-Week High | $16.14 | $746.47 |
52-Week Low | $5.48 | $277.04 |
Enterprise Value | $607.68M | $17.90B |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Fabrinet (FN) trades at $571.78, up 8.48% in the last session, showing strong momentum despite a bearish technical signal. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results expected soon. Analyst consensus remains strongly bullish with 75% buy ratings, supported by Fabrinet's strategic positioning in AI optical manufacturing and robust revenue growth projections.
The outlook remains positive given Fabrinet's critical role in AI infrastructure and strong financial performance, though premium valuation metrics and technical overbought conditions present near-term risks. Continued execution on capacity expansion and AI-driven demand should support long-term growth, but investors should monitor supply chain constraints and competitive pressures.
Trailing returns across standard periods
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →